Cancer Profiling Market Size, Share, Growth, and Industry Analysis, By Type (Immunoassay,Hybridization,NGS,Mass Spectrometry), By Application (Breast,Lung,Prostate,Colorectal), Regional Insights and Forecast to 2035

Cancer Profiling Market Overview

The global Cancer Profiling Market is forecast to expand from USD 15897.59 million in 2026 to USD 17638.38 million in 2027, and is expected to reach USD 40500.42 million by 2035, growing at a CAGR of 10.95% over the forecast period.

In the global Cancer Profiling Market Analysis, the number of cancer profiling tests exceeded 12 million samples in 2024, with instrumentation shipments rising by approximately 36% year-on-year. The Cancer Profiling Market Size evaluation indicates that next-generation sequencing (NGS) based profiling accounted for about 28% of tests in 2024, while immunoassay- and hybridization-based technologies comprised about 21% and 17%, respectively. The Cancer Profiling Market Outlook shows that nearly 55% of profiling is used for solid tumours (breast, lung, colorectal, prostate), highlighting the shift toward precision oncology diagnostics in the B2B clinical genomics sector.

In the United States, the Cancer Profiling Market Size in 2024 encompassed roughly USD 4.2 billion worth of diagnostic testing, representing about 34% of global consumption. U.S. instrumentation shipments numbered approximately 18 000 units in 2024, with NGS-based platforms comprising nearly 30% of U.S. profiling demand. In the U.S., prostate cancer accounted for approximately 34 000 new cases in 2023 while lung cancer recorded 67 160 diagnoses, driving demand for molecular profiling. In the USA Market Outlook, academic and clinical labs together absorb nearly 68% of profiling adoption, making the U.S. a leading region in the Cancer Profiling Market Growth for diagnostics and genomics providers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 72% of oncology labs cite precision medicine utilization as key driver of cancer profiling.
• Major Market Restraint: 38% of laboratories report reimbursement delays as limiting uptake of advanced profiling testing.
• Emerging Trends: 46% of new product launches in 2024 included multiplex gene panels for cancer profiling.
• Regional Leadership: North America holds approximately 42% share of global cancer profiling consumption in 2024.
• Competitive Landscape: Top 10 profiling companies account for about 58% of global market share.
• Market Segmentation: Immunoassay segment holds ~21% of technology share, NGS ~28%, hybridization ~17%.
• Recent Development: 32% of new profiling services launched in 2024 involved liquid biopsy‐based tumour profiling.

Cancer Profiling Market Latest Trends

In Cancer Profiling Market Trends, one significant pattern is the rising adoption of liquid biopsy and NGS platforms for tumour profiling. For example, the NGS segment—estimated at USD 3.9 billion in related oncology diagnostics in 2024—underscores this shift. Cancer profiling immunoassay tests still play a major role in receptor status and protein marker analysis, with roughly 21% of profiling workflows relying on such assays. Meanwhile, hybridization techniques (e.g., FISH, CISH) comprised around 17% of profiling in 2024. The growing number of new cancer cases – the United States projected 1,958,310 new cases in 2023 – increases demand for molecular and proteomic profiling. 

Cancer Profiling Market Dynamics

The dynamics of the cancer profiling market reflect a rapidly expanding industry driven by increasing incidence of cancer, growing demand for precision medicine, and advances in technologies like next-generation sequencing and biomarker discovery. Financially, the market was estimated at roughly US $9.7 billion in 2022 and is forecast to grow to about US $16.0 billion by 2027 (CAGR ~10.6%). Looking further ahead, some forecasts stretch to US $31.4 billion by 2031 (CAGR ~10.3%) and US $23.4 billion by 2032 (CAGR ~9.8%). These numbers underscore the strength of key drivers—such as rising government and private R&D investment, increasingly routine molecular profiling, and broader use of profiling in diagnostics, prognostics and treatment-selection. 

DRIVER

"Rising demand for precision oncology"

A major driver in the Cancer Profiling Market is the increasing emphasis on precision oncology. In 2023, more than 1.9 million new cancer cases were projected in the United States alone, thereby increasing the demand for profiling tests that can guide targeted therapies. Over 60% of oncologists now consider molecular profiling essential in treatment planning for metastatic cases. With hospital networks and diagnostic labs globally deploying over 14 000 new NGS platforms in 2024, the capacity for cancer profiling has expanded significantly. 

RESTRAINT

" Reimbursement and regulatory constraints"

One significant restraint for the Cancer Profiling Market is the reimbursement and regulatory challenge. Approximately 38% of clinical laboratories cite delayed reimbursement as a barrier to deploying advanced profiling tests. Regulatory approval timelines for novel panels average 9-12 months in major markets, limiting commercial adoption. Furthermore, sample preparation and standardisation issues affect around 25% of staged profiling workflows, reducing scalability. 

OPPORTUNITY

" Growth in emerging markets and liquid biopsy"

An important opportunity in the Cancer Profiling Market lies in expansion into emerging markets and growth of liquid biopsy technologies. In Asia-Pacific, profiling labs increased by approximately 18% in 2023, with China, India and Southeast Asia leading. Liquid biopsy portfolios accounted for around 32% of new profiling service launches in 2024. These modalities allow less invasive sampling, can expand access in outpatient settings, and support monitoring of therapy response and minimal residual disease in about 40% of advanced-stage oncology cases. For B2B companies, targeting such markets presents major Cancer Profiling Market Opportunities.

CHALLENGE

" Complexity of data integration and bioinformatics"

A key challenge in the Cancer Profiling Market is managing the complexity of genomic data and integrating it into clinical workflows. Roughly 28% of profiling reports require manual curation owing to variant interpretation hurdles. There is also a shortage of trained bioinformaticians, with 34% of labs reporting staffing deficiencies in genomics data analysis. Additionally, integrating profiling results into electronic health record (EHR) systems remains problematic for about 22% of hospital labs, which impedes adoption of advanced profiling services. 

Cancer Profiling Market Segmentation

Cancer Profiling Market Segmentation refers to the structured division of the global cancer profiling market into specific categories based on technology, biomarker type, application, cancer type, end user, and region. By technology, sequencing techniques such as Next-Generation Sequencing (NGS) dominate the market with around 30.8% share in 2024, owing to their accuracy and efficiency in genetic analysis. Based on biomarker type, the genetic/genomic biomarker segment accounts for approximately 72% of the total market, driven by the growing importance of genomics in cancer diagnostics and treatment. In terms of application, personalized medicine leads with nearly 40.4% share, reflecting the rising adoption of individualized treatment strategies. Regionally, North America remains the largest market, holding over 42.8% of the global share due to advanced healthcare infrastructure and higher investment in oncology research. Overall, this segmentation highlights how the cancer profiling market is distributed across key functional and geographical areas, helping stakeholders identify growth opportunities and target high-value segments effectively.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Immunoassay: The immunoassay segment held around 21% of total profiling workflows in 2024, making it a key technology in the Cancer Profiling Market. This type includes techniques such as ELISA, multiplexed protein assays and immunohistochemistry for biomarker detection. In clinical labs, more than 14 000 immunoassays were performed monthly across oncology centres in 2024. Immunoassay remains preferred for receptor status (e.g., ER/PR in breast cancer), being simpler than genomic tests. In B2B diagnostics, immunoassay vendors continue to expand multiplex panels covering up to 384 protein biomarkers, thereby reinforcing their relevance in the Cancer Profiling Market Trends.

The Immunoassay segment is valued at USD 3,583 million in 2025, holding a 25% share of the Cancer Profiling Market and projected to grow at a CAGR of 10.95% during 2025–2034.

Top 5 Major Dominant Countries in Immunoassay Segment

• United States: Market size USD 1,020 million (28% share, 10.9% CAGR) driven by high adoption of tumor marker screening and ELISA testing in oncology labs.
• Germany: Market size USD 410 million (11% share, 10.7% CAGR) supported by widespread hospital implementation and precision diagnostic programs.
• Japan: Market size USD 380 million (10% share, 11.0% CAGR) owing to high cancer screening rates and early diagnosis initiatives.
• China: Market size USD 350 million (10% share, 11.1% CAGR) supported by rising oncology testing infrastructure.
• United Kingdom: Market size USD 290 million (8% share, 10.8% CAGR) due to expanding biomarker profiling centers and research grants.

Hybridization: Hybridization techniques (such as FISH and CISH for in-situ detection of gene rearrangements) accounted for approximately 17% of profiling workflows in 2024. Nearly 9 000 hospital labs worldwide offered hybridization profiling for key cancers that year. The technique provides spatial and chromosomal context for biomarkers like HER2/neu or ALK rearrangements. Because hybridization systems are established in pathology labs, they serve as a bridge between traditional assays and full genomic profiling. This positions the hybridization segment as a stable and accessible category in the Cancer Profiling Industry Analysis.

The Hybridization segment (FISH/CISH) is projected at USD 2,149 million in 2025, capturing a 15% market share, growing at a CAGR of 10.95% through 2034.

Top 5 Major Dominant Countries in Hybridization Segment

• United States: Market USD 620 million (29% share, 10.9% CAGR) led by integration of genomic hybridization tests across major oncology centers.
• Germany: Market USD 310 million (14% share, 10.7% CAGR) driven by government-funded molecular pathology projects.
• Japan: Market USD 260 million (12% share, 11.0% CAGR) supported by academic hospital expansion.
• China: Market USD 250 million (12% share, 11.1% CAGR) owing to growing cytogenetic testing capacity.
• France: Market USD 200 million (9% share, 10.8% CAGR) boosted by adoption of chromosomal mapping tools.

NGS (Next-Generation Sequencing): NGS dominated with about 28% of profiling workflows in 2024 and corresponds to instrumentation markets valued at around USD 3.9 billion for oncology NGS in 2024. More than 10 500 NGS platforms were operational in oncology labs globally by year-end 2024. NGS enables comprehensive genomic, transcriptomic and epigenomic profiling, enabling detection of hundreds of actionable gene variants. B2B service providers leverage NGS panels ranging from targeted (50-500 genes) to whole exome sequencing, and about 37% of new profiling product launches in 2024 were NGS-based. Therefore the NGS type represents the growth engine in the Cancer Profiling Market Outlook.

The NGS segment is the largest, valued at USD 5,730 million in 2025, representing 40% share, and expanding with a CAGR of 10.95% to 2034.

Top 5 Major Dominant Countries in NGS Segment

• United States: Market USD 1,660 million (29% share, 10.9% CAGR) due to dominant NGS platform deployment and high-volume sequencing labs.
• China: Market USD 950 million (17% share, 11.1% CAGR) with growing precision-medicine initiatives and cancer genomics projects.
• Japan: Market USD 780 million (14% share, 11.0% CAGR) with increasing adoption in university medical centers.
• Germany: Market USD 610 million (11% share, 10.7% CAGR) backed by EU funding for personalized oncology.
• United Kingdom: Market USD 540 million (9% share, 10.8% CAGR) fueled by the 100,000 Genomes Program and clinical NGS use.

Mass Spectrometry: Mass spectrometry-based proteomic profiling currently represents around 9% of workflows in oncology profiling labs, with more than 2 400 units installed globally in 2024. These systems analyse proteomic signatures for several cancers and are increasingly used in biomarker discovery rather than routine diagnostics. Because mass spec requires high technical skill and infrastructure, its adoption is slower but it offers deeper insights into tumour biology, positioning it as an advanced technology category in the Cancer Profiling Market Research Report.

The Mass Spectrometry segment holds USD 865 million market value in 2025, capturing 6% of the Cancer Profiling Market, and expands at a CAGR of 10.95%.

Top 5 Major Dominant Countries in Mass Spectrometry Segment

• United States: Market USD 260 million (30% share, 10.9% CAGR) driven by proteomic biomarker adoption.
• Germany: Market USD 110 million (13% share, 10.7% CAGR) owing to advanced instrument manufacturers.
• Japan: Market USD 100 million (12% share, 11.0% CAGR) with expanding clinical proteomics labs.
• China: Market USD 95 million (11% share, 11.1% CAGR) reflecting biotech investments in analytical testing.
• France: Market USD 80 million (9% share, 10.8% CAGR) through mass spec-based diagnostic R&D.

BY APPLICATION

Breast Cancer: Breast cancer remains the leading application in the Cancer Profiling Market, accounting for approximately 30% of all profiling tests in 2024. An estimated 316,950 new cases are expected in the U.S. in 2025 alone, underscoring demand. Profiling workflows for breast cancer include receptor status (≈ER/PR/HER2) and genomic panels (≥70 genes) and accounted for about 12,000 tests per 100,000 diagnosed cases in large oncology networks. The Breast application segment continues to dominate because of high incidence and well-defined biomarker pathways in the Cancer Profiling Market Share.

The Breast Cancer segment is valued at USD 4,298 million in 2025, accounting for 30% of the Cancer Profiling Market, and continues to expand at a CAGR of 10.95% through 2034.

Top 5 Major Dominant Countries in Breast Cancer Application

• United States: USD 1,290 million, 30% share, 10.9% CAGR, with leading adoption of genomic testing for HER2 and BRCA mutations.
• Germany: USD 650 million, 15% share, 10.7% CAGR, driven by hospital screening programs.
• Japan: USD 610 million, 14% share, 11.0% CAGR, with strong government focus on women’s cancer prevention.
• China: USD 580 million, 13% share, 11.1% CAGR, with 300+ new diagnostic labs established.
• United Kingdom: USD 430 million, 10% share, 10.8% CAGR, driven by NHS digital diagnostics adoption.

Lung Cancer: Lung cancer profiling comprises roughly 22% of the profiling market in 2024. In the U.S., approximately 67,160 new lung cancer cases were projected in 2023. Profiling for EGFR, ALK and ROS1 variants are routine, with more than 85% of advanced non-small cell lung cancer patients undergoing molecular profiling in major centres. The lung cancer segment supports significant adoption of NGS panels and liquid biopsy, thus enhancing its role in the Cancer Profiling Market Trends.

The Lung Cancer segment is projected at USD 3,143 million in 2025, representing 22% of the total market, expanding with a CAGR of 10.95% through 2034.

Top 5 Major Dominant Countries in Lung Cancer Application

• United States: USD 950 million, 30% share, 10.9% CAGR, driven by EGFR and KRAS testing expansion.
• China: USD 620 million, 20% share, 11.1% CAGR, supported by rapid lung screening programs.
• Japan: USD 500 million, 16% share, 11.0% CAGR, driven by hospital NGS adoption.
• Germany: USD 430 million, 14% share, 10.7% CAGR, focused on companion diagnostics.
• United Kingdom: USD 330 million, 10% share, 10.8% CAGR, integrating AI-driven tumor profiling.

Prostate Cancer: Prostate cancer profiling holds about 14% of the market in 2024. U.S. incidence in 2023 was approximately 34,700 cases of new prostate cancer according to U.S. projections. Profiling in prostate cancer includes genomic risk scoring and gene-expression panels used in over 5,000 clinics in the U.S. alone. The Prostate segment offers B2B expansion opportunities for diagnostics companies focusing on risk stratification and precision therapy within the Cancer Profiling Market Outlook.

The Prostate Cancer segment is estimated at USD 2,006 million in 2025, holding 14% of global share, expanding at 10.95% CAGR through 2034.

Top 5 Major Dominant Countries in Prostate Cancer Application

• United States: USD 650 million, 32% share, 10.9% CAGR, with major diagnostic adoption in PSA molecular profiling.
• Germany: USD 290 million, 14% share, 10.7% CAGR, through regional clinical trials.
• Japan: USD 270 million, 13% share, 11.0% CAGR, driven by urology precision testing.
• China: USD 240 million, 12% share, 11.1% CAGR, with expanding male health diagnostics.
• United Kingdom: USD 180 million, 9% share, 10.8% CAGR, due to growing awareness programs.

Colorectal Cancer: Colorectal cancer profiling accounts for around 10% of the profiling volume in 2024. In the U.S., the estimated new colorectal cancer cases reached approximately 28,470 in 2023. Molecular panels covering MSI, KRAS/NRAS and BRAF variants are standard, with over 2,500 labs worldwide offering colorectal profiling services. Because of rising early-onset colorectal incidence (↑8% in people under 50), the colorectal application segment is increasingly relevant in the Cancer Profiling Market Opportunities.

The Colorectal Cancer segment is valued at USD 1,433 million in 2025, representing 10% of the Cancer Profiling Market, and growing at a CAGR of 10.95%.

Top 5 Major Dominant Countries in Colorectal Cancer Application

• United States: USD 430 million, 30% share, 10.9% CAGR, driven by nationwide screening initiatives.
• China: USD 260 million, 18% share, 11.1% CAGR, with clinical biomarker innovation.
• Japan: USD 220 million, 15% share, 11.0% CAGR, focused on early-stage genetic testing.
• Germany: USD 200 million, 14% share, 10.7% CAGR, with molecular pathology standardization.
• United Kingdom: USD 150 million, 10% share, 10.8% CAGR, adopting NGS-based assays.

Regional Outlook for the Cancer Profiling Market

Regional Outlook for the Cancer Profiling Market refers to the analysis of market performance, growth trends, and future opportunities across different geographical regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America currently dominates the global market, accounting for over 42% of total revenue, driven by advanced healthcare infrastructure, high adoption of precision medicine, and strong government and private R&D investments. Europe follows with a significant share due to increased cancer prevalence, supportive regulatory frameworks, and expanding genomics research. The Asia-Pacific region is expected to witness the fastest growth, with a projected CAGR of around 11–12%, fueled by rising healthcare expenditure, growing awareness of personalized medicine, and rapid technological advancements in countries like China, Japan, and India. Meanwhile, Latin America and the Middle East & Africa are emerging markets, showing steady progress due to improving healthcare access and expanding diagnostic facilities. Overall, the regional outlook highlights a dynamic global landscape where developed regions lead in adoption, while developing regions present strong growth potential for future market expansion.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In North America the Cancer Profiling Market is estimated at approximately USD 5.24 billion in 2024, representing about 42% of the global share. The region benefits from high cancer incidence – an estimated 2,041,910 new cancer cases in the U.S. in 2025—and advanced infrastructure, strong reimbursement pathways and labs equipped with genomic platforms. The U.S. alone accounted for over 34% of global test volumes in 2024. Instrumentation installations in North America exceeded 20,000 units across immunoassay, NGS and hybridization systems in 2024. Profiling adoption in hospitals and diagnostics labs is approximately 68% of regional procedures. These attributes make North America a foundational region in the Cancer Profiling Market Growth trajectory for manufacturers and service providers.

The North America Cancer Profiling Market is valued at USD 6,000 million in 2025, representing 42% of the global share, with steady growth due to strong clinical diagnostics and healthcare infrastructure.

North America – Major Dominant Countries

• United States: USD 5,420 million, 90% share, 10.9% CAGR, genomic testing leader.
• Canada: USD 380 million, 6% share, 10.7% CAGR, expanding healthcare diagnostics.
• Mexico: USD 120 million, 2% share, 11.0% CAGR, rising oncology demand.
• Puerto Rico: USD 50 million, 0.8% share, 10.8% CAGR, research center expansion.
• Bermuda: USD 30 million, 0.5% share, 10.7% CAGR, niche clinical adoption.

EUROPE

The Europe Cancer Profiling Market is estimated at roughly USD 2.86 billion in 2024, about 23% of the global share. Germany, UK, France and Italy together accounted for over 55% of European profiling test volumes. Instrument shipments in Europe reached approximately 8,600 units in 2024, with NGS adoption rising by ~14% year-on-year. Hospitals account for ~62% of profiling workflows while research labs cover ~26%. European oncology centres perform over 300,000 molecular profiling tests annually. These dynamics position Europe as a mature market for Cancer Profiling Market Analysis, where growth is supported by reimbursement reforms and precision oncology initiatives.

The Europe Cancer Profiling Market is valued at USD 3,290 million in 2025, accounting for 23% of global share, with strong genomic healthcare policies.

Europe – Major Dominant Countries

• Germany: USD 950 million, 29% share, 10.7% CAGR, innovation hub.
• United Kingdom: USD 650 million, 20% share, 10.8% CAGR, NHS genomics.
• France: USD 520 million, 16% share, 10.9% CAGR, hospital integration.
• Italy: USD 460 million, 14% share, 10.7% CAGR, clinical trials.
• Spain: USD 380 million, 12% share, 10.8% CAGR, personalized testing.

ASIA-PACIFIC

In the Asia-Pacific region, the Cancer Profiling Market size was approximately USD 1.87 billion in 2024, representing around 15% of the global share, with profiling labs increasing by ~18% year-on-year. China, Japan, India and South Korea are the key markets; China alone reported cancer incidence of ~4.82 million new cases in 2022, fueling profiling uptake. Instrument installations across the region exceeded 7,200 units in 2024. Specialty clinics and hospital networks in urban centres performed over 180,000 profiling tests that year. The Asia-Pacific region presents major Cancer Profiling Market Opportunities for diagnostic firms targeting emerging healthcare systems.

The Asia-Pacific Cancer Profiling Market holds USD 2,150 million, 15% global share, led by genomic innovation and rising cancer prevalence.

Asia – Major Dominant Countries

• China: USD 750 million, 35% share, 11.1% CAGR, sequencing expansion.
• Japan: USD 550 million, 26% share, 11.0% CAGR, genomic testing growth.
• India: USD 330 million, 15% share, 11.2% CAGR, diagnostics demand.
• South Korea: USD 270 million, 12% share, 11.0% CAGR, biotech R&D.
• Australia: USD 160 million, 7% share, 10.8% CAGR, clinical research investment.

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for an estimated USD 0.98 billion in 2024, approximately 8% of the global Cancer Profiling Market. Profiling test volumes in the region reached over 62,000 in 2024, with Gulf-Cooperation Council (GCC) countries and South Africa leading adoption. Instrument installations numbered ~2,100 units across hospitals and private diagnostics centres. Government initiatives in cancer genomics and early-detection programmes have increased screening and profiling uptake by ~12% annually. Thus the region, while smaller in size, serves as a growing frontier in the Cancer Profiling Market Outlook for diagnostics providers.

The Middle East & Africa Cancer Profiling Market is valued at USD 860 million in 2025, capturing 6% share, with growing healthcare modernization.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: USD 260 million, 30% share, 10.9% CAGR, oncology advancement.
• UAE: USD 210 million, 24% share, 11.0% CAGR, diagnostic expansion.
• South Africa: USD 150 million, 17% share, 10.8% CAGR, hospital network growth.
• Egypt: USD 120 million, 14% share, 10.9% CAGR, cancer center investment.
• Nigeria: USD 90 million, 10% share, 11.1% CAGR, early detection programs.

List of Top Cancer Profiling Companies

• Ribomed Biotechnologies Inc.
• Foundation Medicine
• Guardant Healt
• Genomic Health
• Nanostring Technologies
• Qiagen N.V.
• Helomics Corporation
• Neogenomics Inc
• Illumina Inc.
• GenomeDx
• Oxford Gene Technology
• HTG Molecular Diagnostics, Inc.
• Caris Life Sciences

Illumina Inc.:  holds an estimated ~18% share of the global cancer profiling instrumentation and services market, leading in NGS-based panels.

Qiagen N.V.: commands approximately ~12% share globally, especially strong in immunoassay and hybridization cancer profiling solutions.

Investment Analysis and Opportunities

Investment in the Cancer Profiling Market remains robust: in 2024 globally more than USD 1.6 billion was invested into cancer profiling R&D and infrastructure, with 42% allocated to NGS and bioinformatics platforms. Capital equipment orders by diagnostic labs increased by ~26% year-on-year. Opportunities abound in emerging geographies: Africa and Latin America profiling labs grew by ~20% in 2024, presenting new markets for B2B diagnostics providers. Moreover, about 34% of profiling test volumes in 2024 were in outpatient or hospital‐based companion diagnostics contexts, indicating potential for expansion. For investors and device/service providers, key Cancer Profiling Market Opportunities include establishing local genomic labs, developing multiplex assays for underserved cancer types, and integrating AI-enabled reporting pipelines. Strategic collaborations and regional partnerships in Asia-Pacific and Middle East markets offer accelerated entry, while consumables and reagent recurring revenue (comprising ~65% of profiling test cost) offer sustainable business models.

New Product Development

Innovation in the Cancer Profiling Market is advancing: in 2024 roughly 46% of new profiling product launches featured multiplex gene panels covering more than 500 genes and targeting over 30 tumour types. About 33% of new launches incorporated liquid biopsy sampling workflows, enabling non-invasive profiling for over 15% of advanced-stage oncology patients. In hybridization/immunoassay space, approximately 22% of new panels in 2024 provided ultra-multiplex protein marker detection (>300 markers) for tumour micro-environment profiling. B2B service providers emphasised turnaround time improvements (average reporting time now <7 days, down from 10 days in 2022) and cost per sample reduction (down ~11% since 2022). These technological innovations reflect the Cancer Profiling Market Trends focusing on speed, depth and accessibility of genomic diagnostics, and support service-provider differentiation and expansion into new clinical workflows.

Five Recent Developments

• In 2023 a leading profiling company launched a 517-gene comprehensive cancer panel covering 30 + tumour types and reduced turnaround time by ~25%.
• In 2024 a diagnostics firm introduced a portable NGS-based tumour profiling workstation enabling hospital decentralisation, installed in over 200 sites by year-end.
• In early 2025 a major player partnered with a cloud-AI vendor to deliver automated variant interpretation for over 4 000 cancer patients per month, increasing throughput by ~18%.
• Also in 2024 a company expanded its multiplex immunoassay panel to include >400 protein biomarkers specifically for tumour micro-environment profiling in 120 cancer institutes.
• In mid-2025 a reagent manufacturer announced a new mass spectrometry-based proteomic tumour-profiling kit that halves sample preparation time and is being piloted in 25 research hospitals.

Report Coverage of Cancer Profiling Market

The Cancer Profiling Market Research Report provides a detailed overview of global market size, by technology and by cancer-type segmentation. It covers profiling test volumes and instrumentation shipments—for example, the NGS segment instrumentation market (~USD 3.9 billion in 2024) and proteomic/mass-spec devices (~2,400 units globally). The report analyses end-use application segments (breast ~30% of tests, lung ~22%, prostate ~14%, colorectal ~10%). Regional procedure volumes are assessed—for instance North America (~42% share), Europe (~23%), Asia-Pacific (~15%), Middle East & Africa (~8%). Competitive landscape profiles companies with dominant shares (Illumina ~18%, Qiagen ~12%) and tracks major new product developments (multiplex panels ~46% of launches in 2024). Investment and market opportunity sections highlight recurring consumables revenue (~65% of test cost) and emerging markets with >20% annual growth in profiling labs. The report is designed for B2B stakeholders—diagnostic manufacturers, service providers, healthcare institutions and investors—to align strategy with Cancer Profiling Market Opportunities, Cancer Profiling Market Growth and Cancer Profiling Market Outlook.

Cancer Profiling Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 15897.59 Million in 2026
Market Size Value By	USD 40500.42 Million by 2035
Growth Rate	CAGR of 10.95% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immunoassay Hybridization NGS Mass Spectrometry By Application : Breast Lung Prostate Colorectal
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample